Single User License
INR 476150
Site License
INR 952299
Corporate User License
INR 1428449

Service Tax Additional

select a format

Single User License
USD 6995
Site License
USD 13990
Corporate User License
USD 20985


Request a quote
Request a Customized research
Request for Sample Report

Recent Viewed Reports

Why Ken Reasearch?


While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"

Fibromyalgia-5EU Drug Forecast and Market Analysis to 2023

Fibromyalgia-5EU Drug Forecast and Market Analysis to 2023

  Request for Sample Report

Executive Summary

Fibromyalgia-5EU Drug Forecast and Market Analysis to 2023


The fibromyalgia market is relatively new and not yet established. Three drugs currently dominate the sales across the 7MM and form the core treatment options; Lyrica, Cymbalta and Savella are all approved in the US while only the former is approved in Japan. Since these drugs are also available in the 5EU for other indications, they are prescribed as off-label therapies. A handful of other genericized products also provide off-label usage including antidepressants, anti-epileptics, opioids and muscle relaxants. Although Lyrica, Cymbalta and Savella can provide an effective treatment regimen, there are ample opportunities for the development of alternative treatment choices which can expand the medications available to patients, providing improvement in efficacy, safety and compliance. By 2023, there will be four new entrants to the market (Lyrica CR, TNX-102 SL, DS-5565 and TD-9855). These new products will help to drive market growth and offset some of the patent expiries of the leading brands during the forecast period. Despite these advancements in the treatment landscape, fibromyalgia therapeutic sales growth are expected to be minimal.

GlobalData estimates that the fibromyalgia market across the 5EU reached sales of approximately USD 149.7m in 2013. The EU market is expected to grow at a slower rate compared with the US, owing to a lack of approved brands and the fact that only one pipeline product is expected to enter the fibromyalgia market during the forecast period.

*This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase.


Overview of Fibromyalgia including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

Detailed information on the key drugs in 5EU including product description, safety and efficacy profiles as well as a SWOT analysis.

Sales forecast for the top drugs in 5EU from 2013-2023.

Analysis of the impact of key events as well the drivers and restraints affecting 5EU Fibromyalgia market.

Reasons To Buy

Understand and capitalize by identifying products that are most likely to ensure a robust return

Stay ahead of the competition by understanding the changing competitive landscape for Fibromyalgia.

Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

Make more informed business decisions from insightful and in-depth analysis of drug performance

Obtain sales forecast for drugs from 2013-2023 in 5EU.

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 5

1.2 List of Figures 7

2 Introduction 8

2.1 Catalyst 8

2.2 Related Reports 8

2.3 Upcoming Related Reports 9

3 Disease Overview 10

3.1 Etiology and Pathophysiology 10

3.1.1 Etiology 10

3.1.2 Pathophysiology 12

3.2 Classification 16

3.3 Symptoms 16

3.4 Quality of Life 17

4 Disease Management 18

4.1 Diagnosis and Treatment Overview 18

4.1.1 Diagnosis 18

4.1.2 Treatment Guidelines and Leading Prescribed Drugs 20

4.1.3 Clinical Practice 22

4.2 France 24

4.3 Germany 25

4.4 Italy 27

4.5 Spain 29

4.6 UK 31

5 Competitive Assessment 34

5.1 Overview 34

5.2 Product Profiles 35

5.2.1 Cymbalta (duloxetine) 35

5.2.2 Savella (milnacipran) 39

5.2.3 Lyrica (pregabalin) 44

5.2.4 Neurontin (gabapentin) 49

5.2.5 Other Antidepressants 52

5.2.6 Opioids 60

5.2.7 Cyclobenzaprine 65

6 Unmet Need and Opportunity 69

6.1 Overview 69

6.2 More Effective and Well-Tolerated Therapies 70

6.2.1 Unmet Need 70

6.2.2 Gap Analysis 72

6.2.3 Opportunity 72

6.3 Increased Drug Approvals 72

6.3.1 Unmet Need 72

6.3.2 Gap Analysis 73

6.3.3 Opportunity 74

6.4 Increased Physician/Patient Awareness and Earlier Diagnosis 74

6.4.1 Unmet Need 74

6.4.2 Gap Analysis 75

6.4.3 Opportunity 75

6.5 Diagnostic Tools 76

6.5.1 Unmet Need 76

6.5.2 Gap Analysis 77

6.5.3 Opportunity 77

7 Pipeline Assessment 78

7.1 Overview 78

7.2 Clinical Trial Mapping 78

7.2.1 Clinical Trials by Class of Therapy 78

7.3 Promising Drugs in Clinical Development 79

7.3.1 Lyrica CR (pregabalin) 82

7.3.2 DS-5565 (mirogabalin) 88

7.3.3 TNX-102 SL (cyclobenzaprine) 94

7.3.4 TD-9855 102

7.4 Other Drugs in Development 107

8 Market Outlook 108

8.1 5EU 108

8.1.1 Forecast 108

8.1.2 Key Events 112

8.1.3 Drivers and Barriers 112

9 Appendix 115

9.1 Bibliography 115

9.2 Abbreviations 125

9.3 Methodology 130

9.4 Forecasting Methodology 130

9.4.1 Diagnosed Fibromyalgia Patients 130

9.4.2 Percentage of Drug-Treated Patients 131

9.4.3 Drugs Included in Each Therapeutic Class 131

9.4.4 Launch and Patent Expiry Dates 131

9.4.5 General Pricing Assumptions 132

9.4.6 Individual Drug Assumptions 133

9.4.7 Generic Erosion 136

9.4.8 Pricing of Pipeline Agents 136

9.5 Primary Research-KOLs Interviewed for This Report 138

9.6 Primary Research-Prescriber Survey 139

9.7 About the Authors 140

9.7.1 Analyst 140

9.7.2 Therapy Area Director 140

9.7.3 Epidemiologist 141

9.7.4 Global Head of Healthcare 141

9.8 About GlobalData 142

9.9 Disclaimer 142

1.2 List of Figures

Figure 1: Fibromyalgia Tender Points 19

Figure 2: Fibromyalgia Therapeutics-Class of Therapy, 2014 79

Figure 3: Fibromyalgia-Phase II-III Pipeline, 2014 80

Figure 4: Competitive Assessment of Late-Stage Pipeline Agents in Fibromyalgia, 2013-2023 81

Figure 5: Clinical and Commercial Positioning of Lyrica CR 86

Figure 6: Clinical and Commercial Positioning of DS-5565 92

Figure 7: Clinical and Commercial Positioning of TNX-102 SL 100

Figure 8: Clinical and Commercial Positioning of TD-9855 106

Figure 9: Sales for Fibromyalgia in the 5EU by Drug Class, 2013-2023 110

Figure 10: Sales for Fibromyalgia in the 5EU by Country, 2013-2023 111

1.1 List of Tables

Table 1: Treatment Guidelines for Fibromyalgia 21

Table 2: Most Commonly Prescribed Drugs for Fibromyalgia by Class in the Global Markets, 2014 22

Table 3: Diagnosis and Treatment of Fibromyalgia, Country Profile-France 25

Table 4: Diagnosis and Treatment of Fibromyalgia, Country Profile-Germany 27

Table 5: Diagnosis and Treatment of Fibromyalgia, Country Profile-Italy 29

Table 6: Diagnosis and Treatment of Fibromyalgia, Country Profile-Spain 31

Table 7: Diagnosis and Treatment of Fibromyalgia, Country Profile-UK 33

Table 8: Leading Branded Drug Treatments for Fibromyalgia in the 7MM, 2014 35

Table 9: Product Profile-Cymbalta 36

Table 10: Cymbalta SWOT Analysis, 2014 38

Table 11: Global Sales Forecasts (USD m) for Cymbalta, 2013-2023 39

Table 12: Product Profile-Savella 40

Table 13: Savella SWOT Analysis, 2014 43

Table 14: Global Sales Forecasts (USD m) for Savella, 2013-2023 44

Table 15: Product Profile-Lyrica 45

Table 16: Lyrica SWOT Analysis, 2014 48

Table 17: Global Sales Forecasts (USD m) for Lyrica, 2013-2023 49

Table 18: Product Profile-Neurontin 50

Table 19: Neurontin SWOT Analysis, 2014 51

Table 20: Global Sales Forecasts (USD m) for Gabapentin, 2013-2023 52

Table 21: Product Profile-Other Antidepressants Frequently Used in the Treatment of Fibromyalgia 55

Table 22: Other Antidepressants Used in the Treatment of Fibromyalgia, SWOT Analysis, 2014 59

Table 23: Global Sales Forecasts (USD m) for Other Antidepressants, 2013-2023 60

Table 24: Product Profile-Opioids 62

Table 25: Opioids SWOT Analysis, 2014 64

Table 26: Global Sales Forecasts (USD m) for Opioids, 2013-2023 65

Table 27: Product Profile-Cyclobenzaprine 66

Table 28: Cyclobenzaprine SWOT Analysis, 2014 68

Table 29: Global Sales Forecasts (USD m) for Cyclobenzaprine, 2013-2023 68

Table 30: Unmet Need and Opportunity in Fibromyalgia 70

Table 31: Comparison of Therapeutic Classes in Development for Fibromyalgia, 2014 81

Table 32: Product Profile-Lyrica CR (pregabalin) 83

Table 33: Lyrica CR SWOT Analysis, 2014 87

Table 34: Global Sales Forecasts (USD m) for Lyrica CR, 2013-2023 88

Table 35: Product Profile-DS-5565 (mirogabalin) 89

Table 36: DS-5565 SWOT Analysis, 2014 93

Table 37: Global Sales Forecasts (USD m) for DS-5565, 2013-2023 94

Table 38: Product Profile-TNX-102 SL (Cyclobenzaprine) 96

Table 39: SWOT Analysis TNX-102 SL, 2014 101

Table 40: Global Sales Forecasts (USD m) for TNX-102 SL, 2013-2023 102

Table 41: Product Profile-TD-9855 103

Table 42: TD-9855 SWOT Analysis, 2014 106

Table 43: Global Sales Forecasts (USD m) for TD-9855, 2013-2023 107

Table 44: Drugs in Development for Fibromyalgia, 2014 107

Table 45: Sales Forecasts (USD m) for Fibromyalgia in the 5EU, 2013-2023 109

Table 46: Key Events Impacting Sales for Fibromyalgia in the 5EU, 2013-2023 112

Table 47: Fibromyalgia Market in the 5EU-Drivers and Barriers, 2013-2023 112

Table 48: Key Launch Dates for Fibromyalgia Drugs in the 7MM 131

Table 49: Key Patent Expiries for the Marketed Drugs Indicated for Fibromyalgia 132

Table 50: High-Prescribing Physicians (Non-KOLs) Surveyed, by Country 139

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@]

Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204


Company Brochure

Engage with Us

query [@]